Suppr超能文献

在埃塞俄比亚一个牧民地区接受抗逆转录病毒治疗的人类免疫缺陷病毒1型患者中,通过深度测序检测到病毒学失败时的遗传多样性和获得性耐药突变。

Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.

作者信息

Tachbele Erdaw, Kyobe Samuel, Katabazi Fred Ashaba, Kigozi Edgar, Mwesigwa Savannah, Joloba Moses, Messele Alebachew, Amogne Wondwossen, Legesse Mengistu, Pieper Rembert, Ameni Gobena

机构信息

Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.

College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

出版信息

Infect Drug Resist. 2021 Nov 18;14:4833-4847. doi: 10.2147/IDR.S337485. eCollection 2021.

Abstract

PURPOSE

This study was conducted to investigate the drug resistance mutations and genetic diversity of HIV-1 in ART experienced patients in South Omo, Ethiopia.

PATIENTS AND METHODS

A cross-sectional study conducted on 253 adult patients attending ART clinics for ≥6 months in South Omo. Samples with VL ≥1000 copies/mL were considered as virological failures (VF) and their reverse transcriptase gene codons 90-234 were sequenced using Illumina MiSeq. MinVar was used for the identification of the subtypes and drug resistance mutations. Phylogenetic tree was constructed by neighbor-joining method using the maximum likelihood model.

RESULTS

The median duration of ART was 51 months and 18.6% (47/253) of the patients exhibited VF. Of 47 viraemic patients, the genome of 41 were sequenced and subtype C was dominant (87.8%) followed by recombinant subtype BC (4.9%), M-09-CPX (4.9) and BF1 (2.4%). Of 41 genotyped subjects, 85.4% (35/41) had at least one ADR mutation. Eighty-one percent (33/41) of viraemic patients harbored NRTI resistance mutations, and 48.8% (20/41) were positive for NNRTI resistance mutations, with 43.9% dual resistance mutations. Among NRTI resistance mutations, M184V (73.2%), K219Q (63.4%) and T215 (56.1%) complex were the most mutated positions, while the most common NNRTI resistance mutations were K103N (24.4%), K101E, P225H and V108I 7.5% each. Active tuberculosis (aOR=13, 95% CI= 3.46-29.69), immunological failure (aOR=3.61, 95% CI=1.26-10.39), opportunistic infections (aOR=8.39, 95% CI= 1.75-40.19), and poor adherence were significantly associated with virological failure, while rural residence (aOR 2.37; 95% CI: 1.62-9.10, P= 0.05), immunological failures (aOR 2.37; 95% CI: 1.62-9.10, P= 0.05) and high viral load (aOR 16; 95% CI: 5.35 51.59, P <0.001) were predictors of ADR mutation among the ART experienced and viraemic study subjects.

CONCLUSION

The study revealed considerable prevalence of VF and ADR mutation with the associated risk indicators. Regular virological monitoring and drug resistance genotyping methods should be implemented for better ART treatment outcomes of the nation.

摘要

目的

本研究旨在调查埃塞俄比亚南奥莫地区接受抗逆转录病毒治疗(ART)的患者中HIV-1的耐药突变和基因多样性。

患者与方法

对南奥莫地区253名在ART诊所接受治疗≥6个月的成年患者进行了一项横断面研究。病毒载量(VL)≥1000拷贝/毫升的样本被视为病毒学失败(VF),并使用Illumina MiSeq对其逆转录酶基因密码子90-234进行测序。使用MinVar鉴定亚型和耐药突变。采用邻接法和最大似然模型构建系统发育树。

结果

ART的中位持续时间为51个月,18.6%(47/253)的患者出现VF。在47例病毒血症患者中,对41例的基因组进行了测序,C亚型占主导(87.8%),其次是重组BC亚型(4.9%)、M-09-CPX(4.9%)和BF1(2.4%)。在41例进行基因分型的受试者中,85.4%(35/41)至少有一个抗逆转录病毒药物(ADR)突变。81%(33/41)的病毒血症患者存在核苷类逆转录酶抑制剂(NRTI)耐药突变,48.8%(20/41)的患者非核苷类逆转录酶抑制剂(NNRTI)耐药突变呈阳性,43.9%为双重耐药突变。在NRTI耐药突变中,M184V(73.2%)、K219Q(63.4%)和T215(56.1%)复合体是突变最多的位点,而最常见的NNRTI耐药突变是K103N(24.4%)、K101E、P225H和V108I(各7.5%)。活动性结核病(调整后比值比[aOR]=13,95%置信区间[CI]=3.46-29.69)、免疫失败(aOR=3.61,95%CI=1.26-10.39)、机会性感染(aOR=8.39,95%CI=1.75-40.19)和依从性差与病毒学失败显著相关,而农村居住(aOR 2.37;95%CI:1.62-9.10,P=0.05)、免疫失败(aOR 2.37;95%CI:1.62-9.10,P=0.05)和高病毒载量(aOR 16;95%CI:5.35-51.59,P<0.001)是接受ART治疗且有病毒血症的研究对象中ADR突变的预测因素。

结论

该研究揭示了VF和ADR突变的相当高的患病率以及相关风险指标。应实施定期的病毒学监测和耐药基因分型方法,以改善该国的ART治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3a/8607991/b2938428d3c2/IDR-14-4833-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验